A reverse-phase HPLC (RP-HPLC) method was developed for strontium ranelate using a full factorial, screening experimental design. The analytical procedure was validated according to international guidelines for linearity, selectivity, sensitivity, accuracy and precision. A separate experimental design was used to demonstrate the robustness of the method. Strontium ranelate was eluted at 4.4 minutes and showed no interference with the excipients used in the formulation, at 321 nm. The method is linear in the range of 20–320 μg mL−1 (R2 = 0.99998). Recovery, tested in the range of 40–120 μg mL−1, was found to be 96.1–102.1 %. Intra-day and intermediate precision RSDs ranged from 1.0–1.4 and 1.2–1.4 %, resp. The limit of detection and limit of quantitation were 0.06 and 0.20 μg mL−1, resp. The proposed technique is fast, cost-effective, reliable and reproducible, and is proposed for the routine analysis of strontium ranelate.
1. J. Y. Reginster, A. Neuprez, N. Dardenne, C. Beaudart, P. Emonts and O. Bruyère, Efficacy and safety of currently marketed anti-osteoporotic medications, Best Pract. Res. Clin. Endocrinol. Metab. 28 (2014) 809–384; https://doi.org/10.1016/j.beem.2014.09.003
3. K. Mythili, S. Gayatri, K. R. Teja, K. Chitra and C. U. M. Reddy, Development and validation of RP-HPLC method for the estimation of strontium ranelate in sachet, Int. J. Pharm. Bio. Sci.2 (2011) 258–263.
4. B. R. C. S. Reddy and N. V. B Rao, A validated stability indicating RP-HPLC method for the determination of strontium ranelate a dual acting bone agent in bulk and sachet dosage form, Rasayan J. Chem.7 (2014) 20–27.
5. H. L. Yin and Y. J. Xu, RP-HPLC determination of strontium ranelate and its related substances, Chin. J. Pharm. Anal.2 (2009) 330–333.
6. A. V. Gajbhar, V. P. Choudhari and B. S. Kuchekar, Development and validation of a HPTLC method for determination of strontium ranelate in the presence of its impurities, Int. J. Pharm. Bio. Sci.6 (2015) 386–394.
7. A. S. Swami, S. A. Pishawikar and H. N. More, UV-spectrophotometric method development and validation for estimation of strontium ranelate in bulk, Int. J. Pharm. Bio. Sci.3 (2012) 171–176.
8. M. Rizk, M. M. A. El-Alamin and M. I. Moawad, A simple kinetic spectrophotometric method for determination of strontium ranelate in bulk and pharmaceutical dosage form, Indo Am. J. Pharm. Res.5 (2015) 2503–2512; https://doi.org/10.1044/1980-iajpr.150701
9. R. C. de Carvalho, A. D. P. Netto and F. F. de Carvalho Marques, Simultaneous determination of strontium ranelate and aspartame in pharmaceutical formulation for the treatment of postmenopausal osteoporosis by capillary zone electrophoresis, Microchem. J.117 (2014) 214–219; https://doi.org/10.1016/j.microc.2014.06.024
10. B. V. Srinivas, U. V. Prasad, M. L. N. Acharyulua and T. S. Reddy, Determination of strontium ranelate in pure and pharmaceutical formulations by oxidimetry, Anal. Chem. Indian J.13 (2013) 205–209.
11. M. Rizk, M. M. A. El-Alamin, H. A. M. Hendawy and M. I. Moawad, Highly sensitive differential pulse and square wave voltammetric methods for determination of strontium ranelate in bulk and pharmaceutical dosage form, Electroanalysis28 (2016) 770–777; https://doi.org/10.1002/elan.201500437
12. Z. I. Szabó, B. Székely-Szentmiklósi, B. Deák, I. Székely-Szentmiklósi, B. Kovács, K. Zöldi and E. Sipos, Study of the effect of formulation variables on the characteristics of combination tablets containing enalapril maleate and indapamide as active substances using experimental design, Acta Pharm. 66 (2016) 191–206; https://doi.org/10.1515/acph-2016-0019
13. A. Gavan, A. Porfire, C. Marina and I. Tomuta, Formulation and pharmaceutical development of quetiapine fumarate sustained release matrix tablets using a QbD approach, Acta Pharm. 67 (2017) 53–70; https://doi.org/10.1515/acph-2017-0009
14. A. M. Kashid, D. A. Ghorpade, P. P. Toranmal and S. C. Dhawale, Development and validation of reversed phase HPLC method for the determination of vildagliptin using an experimental design, J. Anal. Chem. 70 (2015) 510–515; https://doi.org/10.1134/S1061934815040061
15. L. Kumar, M. S. Reddy, R. S. Managuli and P. K. Girish, Full factorial design for optimization, development and validation of HPLC method to determine valsartan in nanoparticles, Saudi Pharm. J.23 (2015) 549–555; https://doi.org/10.1016/j.jsps.2015.02.001
16. M. Carcu-Dobrin, M. Budau, G. Hancu, L. Gagyi, A. Rusu and H. Kelemen, Enantioselective analysis of fluoxetine in pharmaceutical formulations by capillary zone electrophoresis, Saudi Pharm. J.25 (2017) 397–403; https://doi.org/10.1016/j.jsps.2016.09.007
17. L. Eriksson, E. Johansson, N. Kettaneh-Wold, C. Wilkström and S. Wold, Design of Experiments – Principles and Applications, 3rd ed., MKS Umetrics AB, Umeå 2008.
21. P. K. Sahu, N. R. Ramisetti, T. Cecchi, S. Swain, C. S. Patro and J. Panda, An overview of experimen-tal designs in HPLC method development and validation, J. Pharm. Biomed. Anal.147 (2018) 590–611; https://doi.org/10.1016/j.jpba.2017.05.006
22. M. Marusteri and V. Bacarea, Comparing groups for statistical differences: how to choose the right statistical test? Biochem. Med.20 (2010) 15–32; https://doi.org/10.11613/BM.2010.004